The motor features of Parkinson’s have traditionally been the focus of management, but Dr Robin Fackrell argues that in fact non-motor symptoms such as sleep disturbance, constipation and dementia detract from quality of life the most in PD. Robin focuses on identifying these challenging symptoms and managing them effectively. [youtube https://www.youtube.com/watch?v=rwNbY-qSjH0&w=560&h=315]
Dr Boyd Ghosh speaks to delegates about multiple systems atrophy (MSA) and supranuclear palsy (PSP) which are atypical parkinsonian syndromes that are fairly difficult to diagnose in the early stages. Boyd shows delegates videos of patients so that they can learn to recognise how MSA and PSP are different from Parkinson’s disease. For example patients […]
Dr Neil Archibald draws on his experience of setting up and delivering a Parkinson’s service in Teesside to share his successes and pitfalls with people embarking on the same process themselves. Neil’s talk covers how important it is to consider the local incidence and prevalence of Parkinson’s in your area, how to use data to […]
The Parkinson’s Academy draws on a team of expert professionals with a rich blend of skills in treating and managing patients with Parkinson’s. Many of our speakers have a background in both clinical and research work, and so bring to bear both their practical experience as well as their knowledge about the evidence base for […]
The team at Parkinson’s UK know just how important it is that people living with Parkinson’s are cared for by professionals that understand their condition and for that reason is education for professionals is a top priority.
The course will advance understanding of Parkinson’s disease and related movement disorders through taught sessions and mentorship (a mentor will be appointed for each participant). This course will been awarded external CPD credits by the Federation of the Royal Colleges of Physicians.
Background Whether initial treatment for Parkinson’s disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson’s disease.
In general terms patients with Parkinson’s disease are able to drive as long as they are physically and psychologically in a fit state so to do. We all take personal responsibility only to drive when we are able to – this applies to people with Parkinson’s in the same way as it does to the […]
In this edition of the Parkinson’s Academy MasterClass in-house journal, now renamed 'MasterClass: Moving On', Doug MacMahon appropriately reflects on the last 12+ years and how we have gone from nothing to where we are now. Masterclasses 27 and 28 beckon in 2015...